LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Launched by LUTRIS PHARMA LTD. · Feb 14, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a new gel called LUT014 to help reduce skin issues known as acneiform lesions, which can occur in patients being treated for metastatic colorectal cancer (mCRC) with certain medications. The study will compare two strengths of LUT014 gel, applied once daily for four weeks, against a placebo (a non-active treatment) to see which is more effective and safe for patients experiencing these skin problems.

To participate in the trial, patients must be adults aged 18 or older who have been diagnosed with mCRC and are currently receiving FDA-approved treatments like Erbitux® or Vectibix®. They should have Grade 2 or non-infected Grade 3 acneiform lesions. Participants can expect to use the gel daily and attend follow-up visits during the study period. It's important to know that the trial is currently recruiting participants, and there are specific health conditions and recent treatments that could affect eligibility. If you or someone you know is experiencing these skin issues while receiving treatment for mCRC, this study might be a potential opportunity to explore.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed with mCRC;
• • 2. Currently being treated with an FDA approved monoclonal antibody EGFRI for the treatment of mCRC, including but not limited to Erbitux® (cetuximab) Injection and Vectibix® (panitumumab) Injection, as directed by the approved labeling;
• • 3. Grade 2 or Grade 3 non-infected acneiform lesions at the Screening and Baseline;
• • 4. A reversed score of no more than 44 for the skin-specific questions (first 13 questions) of the FACT-EGFRI-18 HRQoL questionnaire at the Screening and Baseline;
• • 5. Age ≥18 years at the time of signing the informed consent form (ICF);
• • 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;
• • 7. Expected life expectancy greater than 3 months;
• • 8. Subject can understand and sign the ICF, can communicate with the Investigator, can understand and comply with the requirements of the protocol, and can apply the study drug by himself/herself or has a care giver that can apply the drug;
• • 9. Women of childbearing potential (WCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 0);
• Exclusion Criteria:
• • 1. Active infection within the treatment area or in other body areas that requires initiation of systemic antibiotics ;
• • 2. Significant skin disease other than EGFRI induced acneiform lesions within the same body areas planned for study drug application;
• • 3. Has a beard that would interfere with administration of study drug and assessment of study endpoints (scoring of lesions);
• • 4. Any cancer other than mCRC within 3 years of Screening, except for carcinoma in situ of the cervix;
• • 5. Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study;
• • 6. Clinically relevant serious co-morbid medical conditions including, but not limited to, unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, active central nervous system (CNS) disease uncontrolled by standard of care, known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements;
• • 7. Pregnant or lactating;
• • 8. Treatment with an EGFRI other than the FDA approved monoclonal antibody EGFRI for the treatment of mCRC within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;
• • 9. Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer. Patients whose mCRC is being treated with a monoclonal antibody EGFRI in combination with a B-Raf inhibitor, such as Erbitux® (cetuximab) Injection in combination with Braftovi® (encorafenib) Capsules, will not be eligible to participate in this trial;
• • 10. Treatment with a systemic corticosteroid 14 days prior to Baseline or treatment with a topical corticosteroid to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0). Patients receiving systemic corticosteroids for 24 hours or less only at the time of chemotherapy infusions (for the prevention or treatment of chemotherapy-induced nausea and vomiting) will be allowed to enroll into this study;
• • 11. Treatment with a topical antibiotic to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0);
• • 12. Initiation of treatment with systemic antibiotic(s) \< 28 days prior to Baseline (Day 0) or any change in dose or frequency of systemic antibiotic(s) within 28 days prior to Baseline. Patients that undergo a washout from systemic antibiotic(s) will be allowed to participate in this trial as long as no systemic antibiotics are taken within 7 days prior to Baseline and they meet all other eligibility criteria;
• • 13. Treatment with any other topical medication applied to the face, neck, or upper portion of the anterior or posterior chest within 7 days prior to Baseline (Day 0).
• • 14. Treatment with an oral retinoid within 30 days or 5 half-lives of the drug prior to Baseline (Day 0), whichever is longer. Patients that undergo a washout from oral retinoids will be allowed to participate
• • 15. Treatment with another investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer;
• • 16. Known hypersensitivity to the inactive ingredients of the study drug (active or placebo).